Pathophysiology and Treatment of Hepatitis C H. C. ThomasJ. BoothJ. Brown Section 1: Keynote Presentations 13 October 2012 Pages: 1 - 8
The Inflammatory Cytokines Michel P. Glauser Section 1: Keynote Presentations 13 October 2012 Pages: 9 - 17
Interleukin-12: Potential Clinical Applications in the Treatment and Prevention of Infectious Diseases Maurice K. GatelyMichael J. Mulqueen Section 1: Keynote Presentations 13 October 2012 Pages: 18 - 26
Fluoroquinolones in Urinary Tract Infections Kurt G. Naher Section 2: The Appropriate Use of Quinolones 13 October 2012 Pages: 27 - 33
The Appropriate Use of Quinolones Alan Percival Section 2: The Appropriate Use of Quinolones 13 October 2012 Pages: 34 - 36
Epidemiology, Control and Treatment of Multiresistant Pneumococci Keith P. Klugman Section 3: Epidemiology, Control and Treatment of Multiresistant Organisms: Pneumococci, Enterococci and MRSA 13 October 2012 Pages: 42 - 46
Epidemiology and Control of Multiresistant Enterococci Roland Leclercq Section 3: Epidemiology, Control and Treatment of Multiresistant Organisms: Pneumococci, Enterococci and MRSA 13 October 2012 Pages: 47 - 49
Epidemiology, Control and Treatment of Methicillin-Resistant Staphylococcus aureus Georg PetersKarsten Becker Section 3: Epidemiology, Control and Treatment of Multiresistant Organisms: Pneumococci, Enterococci and MRSA 13 October 2012 Pages: 50 - 54
Chronic Obstructive Pulmonary Disease Stanley B. Fiel Section 4: Keynote Presentations 13 October 2012 Pages: 55 - 61
New Concepts in the Pathophysiology and Management of Middle Ear Disease in Childhood Stephen I. Pelton Section 4: Keynote Presentations 13 October 2012 Pages: 62 - 67
The Challenge of Changing Healthcare Systems Felix Weber Section 4: Keynote Presentations 13 October 2012 Pages: 68 - 77
Antibiotic Usage: Policy, Clinical and Pharmacoeconomic Outcomes C. Carbon Section 5: Antibiotic Usage: Policy, Clinical and Pharmacoeconomic Outcomes 13 October 2012 Pages: 78 - 79
Antibiotic Usage: Pharmacoeconomic Impact in a Changing Healthcare System Gary Milkovich Section 5: Antibiotic Usage: Policy, Clinical and Pharmacoeconomic Outcomes 13 October 2012 Pages: 80 - 82
Antibiotic Policies Peter Davey Section 5: Antibiotic Usage: Policy, Clinical and Pharmacoeconomic Outcomes 13 October 2012 Pages: 83 - 87
Use of Antimicrobials in Swiss Hospitals Daniel P. LewJorge GarbinoPhilippe Sudre the Swiss Committee of Anti-Infective Agents Section 5: Antibiotic Usage: Policy, Clinical and Pharmacoeconomic Outcomes 13 October 2012 Pages: 88 - 91
Discussion: Section 5 Section 5: Antibiotic Usage: Policy, Clinical and Pharmacoeconomic Outcomes 13 October 2012 Pages: 92 - 94
Epidemiology, Control and Treatment of Multiresistant Gram-Negative Rods Bernd Wiedemann Section 6: Epidemiology, Control and Treatment of Multiresistant Organisms: Gram-Negative Rods and Tuberculosis 13 October 2012 Pages: 95 - 102
Epidemiology, Control and Treatment of Multidrug-Resistant Tuberculosis Pierre ChauletMario RaviglioneFlavia Bustreo Section 6: Epidemiology, Control and Treatment of Multiresistant Organisms: Gram-Negative Rods and Tuberculosis 13 October 2012 Pages: 103 - 108